Related references
Note: Only part of the references are listed.Aminoglycoside drugs induce efficient read-through of CDKL5 nonsense mutations, slightly restoring its kinase activity
Maria Fazzari et al.
RNA BIOLOGY (2019)
The Spectrum of PAX6 Mutations and Genotype-Phenotype Correlations in the Eye
Dulce Lima Cunha et al.
GENES (2019)
Novel variants in PAX6 gene caused congenital aniridia in two Chinese families
R. Zhang et al.
EYE (2017)
Efficacy of Postnatal In Vivo Nonsense Suppression Therapy in a Pax6 Mouse Model of Aniridia
Xia Wang et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2017)
PAX6 aniridia syndrome: clinics, genetics, and therapeutics
Hyun Taek Lim et al.
CURRENT OPINION IN OPHTHALMOLOGY (2017)
Determination of ETV6-RUNX1 genomic breakpoint by next-generation sequencing
Yanliang Jin et al.
CANCER MEDICINE (2016)
Nonsense-mediated mRNA decay in humans at a glance
Tatsuaki Kurosaki et al.
JOURNAL OF CELL SCIENCE (2016)
Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression
Bijoyita Roy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives
Ivana Pibiri et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
Translational read-through of the RP2 Arg120stop mutation in patient iPSC-derived retinal pigment epithelium cells
Nele Schwarz et al.
HUMAN MOLECULAR GENETICS (2015)
Postnatal manipulation of Pax6 dosage reverses congenital tissue malformation defects
Cheryl Y. Gregory-Evans et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Ataluren as an Agent for Therapeutic Nonsense Suppression
Stuart W. Peltz et al.
ANNUAL REVIEW OF MEDICINE, VOL 64 (2013)
Sense from nonsense: therapies for premature stop codon diseases
Laure Bidou et al.
TRENDS IN MOLECULAR MEDICINE (2012)
Statistical Analysis of Readthrough Levels for Nonsense Mutations in Mammalian Cells Reveals a Major Determinant of Response to Gentamicin
Celia Floquet et al.
PLOS GENETICS (2012)
Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases
Kim M. Keeling et al.
WILEY INTERDISCIPLINARY REVIEWS-RNA (2011)
Aminoglycoside-Mediated Partial Suppression of MECP2 Nonsense Mutations Responsible for Rett Syndrome In Vitro
Andreea C. Popescu et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2010)
Proximity of the poly(A)-binding protein to a premature termination codon inhibits mammalian nonsense-mediated mRNA decay
Ana Luisa Silva et al.
RNA (2008)
A conserved role for cytoplasmic poly(A)-binding protein 1 (PABPC1) in nonsense-mediated mRNA decay
Isabelle Behm-Ansmant et al.
EMBO JOURNAL (2007)
WAGR syndrome: A clinical review of 54 cases
BV Fischbach et al.
PEDIATRICS (2005)
PAX6 mutations: genotype-phenotype correlations
I Tzoulaki et al.
BMC GENETICS (2005)
In vitro analysis of aminoglycoside therapy for the Arg 120stop nonsense mutation in RP2 patients
C Grayson et al.
JOURNAL OF MEDICAL GENETICS (2002)
Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system
M Manuvakhova et al.
RNA (2000)
Share Paper
